Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), ...

CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone ...

Application supported by Phase 3 data reinforcing teclistamab regimens as a potential standard of care after at least one prior therapy1 Teclistamab monotherapy delivered superior progression-free ...

In this phase 2 study, researchers aimed to evaluate the effectiveness of tyrosine kinase inhibition in relapsed or refractory germ cell tumors.

There’s a newly approved treatment for multiple myeloma that has returned after earlier therapy. The combination of Tecvayli ...

In a phase 1–2 trial, teclistamab, a bispecific antibody targeting CD3 on T-cell surfaces and B-cell maturation antigen on myeloma cells, showed durable responses in heavily pretreated patients with ...

OS of 8.9 months versus 5.8 months with trifluridine/tipiracil alone, supporting phase III ...

LONDON, March 10, 2026 /PRNewswire/ -- The "Checkpoint Inhibitor Refractory Cancer Drugs Market - Growth, Share, Opportunities & Competitive Analysis, 2025 - 2032" report has been added to the ...

Dr. David Faxon answers the question: 'Alternate Therapy For Refractory Angina?' — -- Question: What alternative therapies are there for patients with refractory angina (angina that does not ...

The experimental drug erenumab (AMG 334, Amgen and Novartis) is effective and safe in patients with episodic migraine in whom previous treatments have failed, results of a new phase 3b trial have ...

Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacy Topline data ...